Table 3 Difference of characteristics between the study subgroups
Characteristics | Disease duration | P value | |
|---|---|---|---|
< 5 years, n = 48 | ≥ 5 years, n = 44 | ||
Age (year), mean ± SD | 46.6 ± 15.2 | 50.7 ± 17.8 | 0.232 |
Male/Female, n (%) | 33 / 15 (68.8/31.2) | 31/13 (70.5/29.5) | |
Disease duration (year), mean ± SD | 2.1 ± 1.3 | 12.7 ± 6.5 | < 0.001 |
Disease extent, n (%) | |||
Extensive colitis | 31 (64.6) | 26 (59.1) | |
Left sided colitis | 8 (16.7) | 16 (36.4) | |
Proctitis | 9 (18.7) | 2 (4.5) | |
CAI (Lichtiger’s socre) mean ± SD | 2.5 ± 2.9 | 1.3 ± 1.7 | 0.016 |
eMayo mean ± SD | 1.1 ± 1.0 | 0.9 ± 1.0 | 0.250 |
eMayo 0, n (%) | 16 (33.3) | 22 (50.0) | |
eMayo 1, n (%) | 13 (27.1) | 8 (18.2) | |
eMayo 2, n (%) | 16 (33.3) | 11 (25.0) | |
eMayo 3, n (%) | 3 (6.2) | 3 (6.8) | |
UCEIS score mean ± SD | 2.4 ± 1.9 | 1.8 ± 1.9 | 0.146 |
PGE-MUM (μ•g−1•Cr− 1) mean ± SD | 32.3 ± 16.8 | 25.8 ± 19.5 | 0.088 |
FIT (ng/ml), n (%) mean ± SD | 3285.8 ± 5953.5 | 969.6 ± 2118.1 | 0.017 |
Medication at study, n (%) | |||
Oral 5-ASA | 25 (52.1) | 33 (75) | |
Suppository 5-ASA | 10 (20.8) | 7 (15.9) | |
Systemic steroids | 9 (18.8) | 3 (6.8) | |
Azathioprine/Mercaptopurine | 22 (45.8) | 13 (29.5) | |
Tacrolimus | 7 (14.6) | 3 (6.8) | |
Biologics | 13 (27.1) | 12 (27.3) | |